DrugPatentWatch Database Preview
AZEDRA Drug Profile
When do Azedra patents expire, and when can generic versions of Azedra launch?
Azedra is a drug marketed by Progenics Pharms Inc and is included in one NDA.
The generic ingredient in AZEDRA is iobenguane i-131. One supplier is listed for this compound. Additional details are available on the iobenguane i-131 profile page.
Summary for AZEDRA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 7 |
Clinical Trials: | 2 |
DailyMed Link: | AZEDRA at DailyMed |

Generic Entry Opportunity Date for AZEDRA
Generic Entry Date for AZEDRA*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for AZEDRA
(m-((sup 131)I)Iodobenzyl)guanidine |
(m-Iodo-(sup 131)I-benzyl)guanidine |
[131]I-MIBG |
[131I]mIBG |
131I-m-Iodobenzylguanidine |
131I-MIBG |
2-[(3-iodophenyl)methyl]guanidine |
3-Iodobenzylguanidine |
3-Iodobenzylguanidine (131I) (JAN) |
77679-27-7 |
AC1L2FP4 |
AC1Q50E4 |
Azedra (TN) |
CHEBI:135997 |
CHEMBL1615779 |
D03308 |
D05FQD |
DTXSID30228311 |
Guanidine, ((3-(iodo-(sup 131)I)phenyl)methyl)- |
Guanidine, ((3-iodo-131I)phenyl)methyl)- |
I-131 meta-iodobenzyl guanidine |
I-131 Metaiodobenzylguanidine |
I-131 MIBG |
Iobeguane I 131 |
Iobeguane I 131 [USAN] |
Iobenguane ((sup 131)I) |
Iobenguane ((sup 131)I) [INN] |
Iobenguane (131I) |
Iobenguane (131I) [INN] |
Iobenguane I 131 |
Iobenguane I 131 (USP) |
Iobenguane I 131 [USAN:USP] |
Iobenguane I131 |
Iobenguane iobenguane ((sup 131)I) |
Iobenguane Sulfate I 123 (iobenguane (131 I)) |
Iobenguane[131I] |
Iobenguano (131 I) |
Iobenguano (131 I) [Spanish] |
Iobenguanum (131 I) |
Iobenguanum (131 I) [Latin] |
Iobenguanum (313 I) [Latin] |
LS-177380 |
m-[123I/125I/131I]MIBG |
m-131-Iodobenzylguanidine |
m-Iodobenzylguanidine |
M131IBG |
meta-Iodobenzylguanidine (MIBG) labeled with iodine-131 |
Metaiodobenzylguanidine I-131 |
MIBG-(131 I) |
MIBG[Radioiodinated] |
MOLI000967 |
MyoMIBG-123I injection |
PDWUPXJEEYOOTR-JRGAVVOBSA-N |
Pheo MIBG-131I injection |
PheoMIBG-I 131 (TN) |
PheoMIBG-I(131) Injection |
Q461L7AK4R |
SCHEMBL13092741 |
Ultratrace iobenguane 131I |
Ultratrace iobenguane I131 |
Ultratrace MIBG |
UNII-Q461L7AK4R |
US Patents and Regulatory Information for AZEDRA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Progenics Pharms Inc | AZEDRA | iobenguane i-131 | SOLUTION;INTRAVENOUS | 209607-001 | Jul 30, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
Progenics Pharms Inc | AZEDRA | iobenguane i-131 | SOLUTION;INTRAVENOUS | 209607-001 | Jul 30, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |